COGT Cogent Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: COGT
Price (delayed)
$14.89
Market cap
$2.08B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.78
Enterprise value
$2.01B
Relative Growth:
Rel. Growth:
4
Relative Strength:
Rel. Strength:
90
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
3
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed
Highlights
The company's equity has shrunk by 58% YoY and by 29% QoQ
Cogent Biosciences's quick ratio has plunged by 55% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of COGT
Market
Valuations
Earnings
Shares outstanding
139.7M
Market cap
$2.08B
Enterprise value
$2.01B
Price to earnings (P/E)
N/A
Price to book (P/B)
10.94
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$299.66M
Net income
-$284.08M
EBIT
-$283.76M
EBITDA
-$279.26M
Free cash flow
-$234.65M
Per share
Balance sheet
Liquidity
EPS
-$1.78
EPS diluted
-$1.78
Free cash flow per share
-$2.05
Book value per share
$1.36
Revenue per share
$0
TBVPS
$2.4
Total assets
$274.82M
Total liabilities
$119.78M
Debt
$60.66M
Equity
$155.04M
Working capital
$186.59M
Debt to equity
0.39
Current ratio
4.19
Quick ratio
4.07
Net debt/EBITDA
0.24
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-89.4%
Return on equity
-120.2%
Return on invested capital
-158%
Return on capital employed
-131.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COGT stock price
How has the Cogent Biosciences stock price performed over time
Intraday
3.26%
1 week
-8.14%
1 month
-6.35%
1 year
42.08%
YTD
90.9%
QTD
3.69%
Financial performance
How have Cogent Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$299.66M
Net income
-$284.08M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 25% YoY and by 5% QoQ
COGT's operating income is down by 23% year-on-year and by 3.9% since the previous quarter
Price vs fundamentals
How does COGT's price correlate with its fundamentals
Growth
What is Cogent Biosciences's growth rate over time
Valuation
What is Cogent Biosciences stock price valuation
P/E
N/A
P/B
10.94
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 6% QoQ and by 4.1% YoY
The P/B is 172% above the last 4 quarters average of 3.9
The company's equity has shrunk by 58% YoY and by 29% QoQ
Efficiency
How efficient is Cogent Biosciences business performance
COGT's return on invested capital has dropped by 84% year-on-year and by 30% since the previous quarter
The company's return on equity has shrunk by 79% YoY and by 30% QoQ
The ROA has plunged by 55% YoY and by 18% from the previous quarter
Dividends
What is COGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COGT.
Financial health
How did Cogent Biosciences financials performed over time
Cogent Biosciences's total assets is 129% higher than its total liabilities
The total liabilities has surged by 111% year-on-year and by 85% since the previous quarter
Cogent Biosciences's quick ratio has plunged by 55% YoY and by 18% from the previous quarter
The company's debt is 61% lower than its equity
The company's equity has shrunk by 58% YoY and by 29% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.